Skip to main content
Natco Pharma Ltd. logo

Natco Pharma Ltd. — Investor Relations & Filings

Ticker · NATCOPHARM ISIN · INE987B01026 LEI · 33580086GIBRWXSNGG39 BSE.NS Manufacturing
Open in API
Filings indexed 1,708 across all filing types
Latest filing 2020-11-12 Regulatory Filings
Country IN India
Listing BSE.NS NATCOPHARM

About Natco Pharma Ltd.

https://www.natcopharma.co.in/

Natco Pharma Ltd. is a vertically integrated organization focused on the development, manufacturing, and marketing of complex generics and active pharmaceutical ingredients (APIs). The company specializes in niche therapeutic areas, maintaining a leadership position in oncology and a significant presence in specialty segments such as hepatology, cardiology, and diabetology. Natco is recognized for its expertise in high-barrier-to-entry products, including complex oral solids and injectables. Its business model emphasizes research and development to deliver affordable versions of life-saving medicines globally. With a robust portfolio of finished dosage formulations and a strong supply chain for APIs, the company serves diverse international markets, including North America, Europe, and emerging economies, through strategic partnerships and direct distribution channels.

Recent filings

Filing Released Lang Actions
Financial Result Updates
Regulatory Filings
2020-11-12 English
Unaudited Financial Results for the Quarter and Half year ended 30th September, 2020
Regulatory Filings
2020-11-12 English
The Company will host an Earnings Call with Investors / Analysts at 11.00 a.m. IST on Friday, November 13, 2020 to disseminate Financial Results of the company for the quarter ended September ....
Regulatory Filings
2020-11-06 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 95% confidence The document is a notification about an upcoming earnings call for the quarter ended September 30, 2020 (Q2 FY21). It includes details about the date, time, participants, and dial-in information for the call. There is no actual financial data or results presented in the document, only an announcement of the call where such information will be discussed. The document length is short (2693 characters) and it primarily serves to inform about the earnings call event rather than provide the earnings results themselves. Therefore, it fits the category of a Call Transcript (CT) announcement or invitation rather than the transcript itself. However, since the document is announcing the earnings call and not the transcript, the best fitting category is Call Transcript (CT) as it relates directly to the earnings call event.
2020-11-06 English
Natco Pharma Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled to be held on November 12, 2020, inter alia, to consider the following items of ....
Regulatory Filings
2020-11-03 English
Trading Window
AGM Information Classification · 85% confidence The document is very short (315 characters) and lists agenda items for a meeting, including consideration of unaudited financial results for a quarter and half-year period ending 30th September 2020, and consideration of a second interim dividend for the financial year 2020-21. This suggests it is an announcement or notice related to a meeting agenda rather than the actual financial report or dividend declaration. The presence of agenda items and the brevity indicate it is likely a notice or invitation to a meeting where these items will be discussed, which aligns with AGM Information (AGM-R) filings that typically include meeting agendas and materials shared during the Annual General Meeting or similar meetings. It is not a full financial report (IR or 10-K), nor a dividend declaration (DIV), but rather a meeting agenda document.
2020-11-03 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.